Hot Topics in NASH: Current Controversies and New Developments in Fatty Liver Disease

The popular Hot Topics series returns with new timely topics and insightful discussion by our faculty panel on key challenges faced managing your patients with NASH.


Program length (45 minutes)

  • Welcome and Introduction
  • Case-Based Presentation
  • Discussion and Audience Question and Answer Session


Date / Time
Event Details


Rita Basu, MD

Professor of Medicine
Clinical Education Director of Center for Diabetes Technology 
Division of Endorcinology
Vice Chair of IRB-HSR
University of Virginia
Charlottesville, Virginia

Rotonya Carr, MD

Assistant Professor of Medicine
Division of Gastroenterology
University of Pennsylvania
Philadelphia, Pennsylvania

Kenneth Cusi, MD, FACP, FACE

Chief, Division of Endocrinology, Diabetes and Metabolism
The University of Florida
Gainesville, Florida

Juan Frias, MD

President and CEO
National Research Institute
Los Angeles, California

Stephen Harrison, MD

Visiting Professor of Hepatology 
Radcliffe Department of Medicine
University of Oxford
Oxford, United Kingdom

Philip N. Newsome, PhD, FRCPE

Professor of Hepatology
University of Birmingham
Birmingham, United Kingdom

Raymond Soccio, MD

Assistant Professor of Medicine
Division of Endocrinology, Diabetes, and Metabolism
University of Pennsylvania Health System
Crescenz Philadelphia VA Medical Center
Philadelphia, Pennsylvania

Brent A. Tetri, MD

Professor of Internal Medicine
Division of Gastroenterology and Hepatology
Saint Louis University School of Medicine
St Louis, Missouri

Goal Statement
The goal of this activity is to improve participants’ competence in identifying and managing patients with or at risk for NASH and in knowledge of emerging NASH therapies and diagnostic tests.

Target Audience 
This program is intended for gastroenterologists, hepatologists, endocrinologists, and other healthcare providers who care for patients with or at risk for NASH.

Learning Objectives

  • Evaluate risk and apply appropriate methodology to characterize NAFLD and diagnose NASH in individual patients
  • Apply best practices in the management of patients with NAFLD based on evolving data on lifestyle modification and medical treatment
  • Critically evaluate data on emerging therapies for NASH, including evidence of reversal of fibrosis, risks and benefits, and their potential utility in the treatment of patients with NASH
  • Demonstrate an understanding of clinical trial design and evaluation of endpoints in the setting of NAFLD/NASH


Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Gastroenterological Association and Clinical Care Options, LLC. American Gastroenterological Association is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
American Gastroenterological Association designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

Disclosure of Conflicts of Interest
AGA requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. AGA is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.